Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Identification of candidate risk gene variations by whole-genome sequence analysis of four rat strains commonly used in inflammation research.
Mind-body medicine for multiple sclerosis: a systematic review.
Progressive multiple sclerosis: pathology and pathogenesis.
Multiple sclerosis and herpesvirus interaction.
Defining the new end point for multiple sclerosis treatment.
Choosing the best treatment for multiple sclerosis: comparative effectiveness, safety, and other factors involved in disease-modifying therapy choice.
Combinatorial actions of Tgfβ and Activin ligands promote oligodendrocyte development and CNS myelination.
Cognitive reserve in multiple sclerosis: Protective effects of education.
CSF abnormalities can be predicted by VEP and MRI pathology in the examination of optic neuritis.
The organization of the sphingosine 1-phosphate signaling system.
Pure sensory Guillain-Barré syndrome: A case report and review of the literature.
Pediatric Multiple Sclerosis-A Challenging Demyelinating Disease: Case Report and Brief Review of the Literature.
The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders.
Prevalence of Lhermitte's sign in multiple sclerosis versus neuromyelitis optica.
Experiences of functional electrical stimulation (FES) and ankle foot orthoses (AFOs) for foot-drop in people with multiple sclerosis.
Riboflavin Supplementation to Patients with Multiple Sclerosis does not Improve Disability Status nor is Riboflavin Supplementation Correlated to Homocysteine.
Endovascular Treatment of Chronic Cerebro-Spinal Venous Insufficiency in Multiple Sclerosis: A retrospective study.
Epimedium flavonoids ameliorate experimental autoimmune encephalomyelitis in rats by modulating neuroinflammatory and neurotrophic responses.
Opexa's Tovaxin® for the Treatment of Multiple Sclerosis Granted Fast Track Designation by FDA
A Distinct Class of Antibodies May Be an Indicator of Gray Matter Autoimmunity in Early and Established Relapsing Remitting Multiple Sclerosis Patients.
How can we exploit the brain's ability to repair itself?
Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis.
Bioenergetics of the spinal cord in experimental autoimmune encephalitis of rats.
Monitoring neuromyelitis optica activity.
Blood-Brain Barrier Disruption is More Severe in Neuromyelitis Optica than in Multiple Sclerosis and Correlates with Clinical Disability.

Pages